Alisol A 24-acetate

Synonyms: Alisol A 24-monoacetate; Alisol A monoacetate
Alisol A 24-acetate(Alisol A monoacetate)是一种口服活性的原萜烷型四环三萜类化合物衍生物,可上调脂联素、AMPKα、CPT1、ACOX1,下调SREBP-1c、ACC、FAS、Bcl-2、Bcl-xl、PPAR-γ、perilipin A及NFATc1的表达,抑制PI3K/Akt/mTOR及HMGR的活性,激活PKA和ERK信号通路,并调控细胞凋亡(apoptosis)、自噬(Autophagy)、肝脏脂质蓄积、炎症反应、神经保护、MRSA膜完整性以及破骨细胞分化,因此可用于非酒精性脂肪肝病、肾毒性、肥胖症、全脑缺血再灌注损伤、细菌感染及骨质疏松症的相关研究。
产品编号: MS-A35435 纯度: 98.0% CAS No.: 18674-16-3 分子式: C32H52O6 分子量: 532.75
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Alisol A 24-acetate(Alisol A monoacetate)是一种口服活性的原萜烷型四环三萜类化合物衍生物,可上调脂联素、AMPKα、CPT1、ACOX1,下调SREBP-1c、ACC、FAS、Bcl-2、Bcl-xl、PPAR-γ、perilipin A及NFATc1的表达,抑制PI3K/Akt/mTOR及HMGR的活性,激活PKA和ERK信号通路,并调控细胞凋亡(apoptosis)、自噬(Autophagy)、肝脏脂质蓄积、炎症反应、神经保护、MRSA膜完整性以及破骨细胞分化,因此可用于非酒精性脂肪肝病、肾毒性、肥胖症、全脑缺血再灌注损伤、细菌感染及骨质疏松症的相关研究。

生物实验数据

生物活性 Alisol A 24-acetate (Alisol A monoacetate) is an orally active protostane-type tetracyclic triterpenoid derivative that upregulates adiponectin, AMPKα, CPT1, and ACOX1; downregulates the expression of SREBP-1c, ACC, FAS, Bcl-2, Bcl-xl, PPAR-γ, perilipin A, and NFATc1; inhibits the activities of PI3K/Akt/mTOR and HMGR; activates the PKA and ERK signaling pathways; and regulates apoptosis, autophagy, hepatic lipid accumulation, inflammatory responses, neuroprotection, MRSA membrane integrity, and osteoclast differentiation, thereby being applicable to research on non-alcoholic fatty liver disease, nephrotoxicity, obesity, global cerebral ischemia-reperfusion injury, bacterial infection, and osteoporosis.
IC50 & Target

PKA

 

ERK

 

AMPK

 

PPARα

 

CPT-1

 

PI3K

 

Bcl-xL

 

Bcl-2

 

PPAR-γ

 

体外研究
(In Vitro)

Alisol A 24-acetate (2.5-100 μM; 24 h) 可呈剂量依赖性降低 HepG2 细胞活力,孵育 24 h 后,浓度高于 10 μM 时可观察到显著的细胞毒性。
Alisol A 24-acetate (10 μM; 24 h) 可改善游离脂肪酸诱导的 HepG2 细胞脂质蓄积与炎症反应,减少脂滴形成、阳性脂质及胞内甘油三酯含量,降低细胞上清液中 TNF-α、IL-6 水平,同时上调脂联素的蛋白与 mRNA 表达;该物质可激活 AMPKα 磷酸化并提升 AMPK mRNA 表达,在转录及蛋白层面下调 SREBP-1c、ACC、FAS,上调 CPT1、ACOX1,且对 PPARα 表达无明显影响。
Alisol A 24-acetate (compound 24A) (3-768 μM; 24 h) 以浓度依赖的方式降低 HK-2 细胞活力,其中 6 μM 处理后细胞活力为 96.20%,可用于后续实验。
Alisol A 24-acetate (6 μM; 24 h) 可下调 Bcl-2、Bcl-xl 的蛋白与 mRNA 表达以诱导 HK-2 细胞凋亡,上调 Kim-1、Clusterin、TFF-3 的蛋白及 mRNA 表达引发细胞肾毒性;同时通过升高 LC3II/LC3I 比值、上调 Beclin-1 与 LC3 的蛋白和 mRNA 水平,并抑制 PI3K/Akt/mTOR 通路,共同诱导 HK-2 细胞发生自噬。
Alisol A 24-acetate (6 μM; 48 h) 诱导的自噬可介导 HK-2 细胞的凋亡与肾毒性,因为与自噬抑制剂 3-MA 共孵育可逆转细胞活力丧失、降低 LC3II/LC3I 比值、上调抗凋亡蛋白 Bcl-2 并下调肾毒性生物标志物 Kim-1。
Alisol A 24-acetate (AA-24-a) (10-50 μM; 24-72 h) 可提高完全分化的 3T3-L1 脂肪细胞的存活率;可显著刺激完全分化的 3T3-L1 脂肪细胞的基础脂解作用。
Alisol A 24-acetate (50 μM; 12 h) 可改变完全分化的 3T3-L1 脂肪细胞中脂解相关基因的表达,上调 ATGL mRNA 水平,同时下调 HSL、PPARγ 和 perilipin A mRNA 水平。
Alisol A 24-acetate (30-50 μM; 20-36 h) 可增加完全分化的 3T3-L1 脂肪细胞中 ATGL 蛋白的表达和 HSL 在 Ser660 位点的磷酸化,同时激活 ERK 并降低 PPARγ 和 perilipin A 蛋白的水平。
Alisol A 24-acetate 在完全分化的 3T3-L1 脂肪细胞中诱导的脂解作用部分由 PKA 诱导的 HSL 在 Ser660 位点的磷酸化介导。
Alisol A 24-acetate (30-50 μM; 20 h) 可诱导完全分化的 3T3-L1 脂肪细胞发生脂解作用,该效应由 ERK 通路激活介导,通路活化进一步下调 PPARγ 和 perilipin A 表达;PD98059 (MS-N60869) 预处理可减少甘油释放并逆转上述分子改变。
Alisol A 24-acetate (24A) 可降低 HepG2 细胞中炎症因子 TNF−α、IL-1β、IL-6 和 IL-8 的水平;对氧糖剥夺损伤的脑微血管内皮细胞紧密连接起到保护作用;强效抑制 MRSA HMGR。
Alisol A 24-acetate (AA) 是 MRSA HMGR 的高亲和力配体,其 Kd 值为 30 μM。
Alisol A 24-acetate (20-40 μM; 24 h) 对 RAW 264.7 巨噬细胞和原代主动脉内皮细胞 HAEC 无细胞毒性。
Alisol A 24-acetate (10-40 μM) 以剂量依赖的方式提升金黄色葡萄球菌 ATCC 43300 的膜流动性。
Alisol A 24-acetate (20-50 μM) 可呈剂量依赖性地破坏金黄色葡萄球菌 ATCC 43300 的膜电位和膜完整性。
Alisol A 24-acetate (10-40 μM; 1-1.5 h) 可在 37 °C 孵育 1.5 h 后,以剂量依赖的方式提升金黄色葡萄球菌 ATCC 43300 的细胞内 ATP 水平和 ROS 水平。
Alisol A 24-acetate 对金黄色葡萄球菌 ATCC 43300 造成形态损伤 (不规则凹陷、表面塌陷)。
Alisol A 24-acetate (1-30 μM; 4 days) 可剂量依赖性地抑制 RANKL 和 M-CSF 诱导的小鼠骨髓来源巨噬细胞向破骨细胞分化。
Alisol A 24-acetate (10 μM; 30 min pre-incubation, 1-3 days RANKL stimulation) 可在 3 天刺激过程中显著抑制小鼠骨髓来源巨噬细胞中 RANKL 诱导的 NFATc1、TRAP、DC-STAMP 和组织蛋白酶 K 的 mRNA 表达。
Alisol A 24-acetate (预孵育 1 小时,RANKL 刺激 1-3 天) 可在 3 天刺激过程中显著抑制小鼠骨髓来源巨噬细胞中 RANKL 诱导的 NFATc1 蛋白表达

Cell Viability Assay

Cell Line: HepG2 cells
Concentration: 2.5 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Reduced HepG2 cell viability in a dose-dependent manner.
Reduced viability at concentrations from 2.5 μM to 100 μM.
Caused significant inhibition of cell proliferation at concentrations above 10 μM.
Induced 23.85% cytotoxicity at 20 μM.

ELISA Assay

Cell Line: FFA-induced HepG2 cellular steatosis model
Concentration: 10 μM
Incubation Time: 24 h
Result: Significantly reduced TNF-α, IL-6 levels in HepG2 cell supernatants.

RT-PCR

Cell Line: FFA-induced HepG2 cellular steatosis model
Concentration: 10 μM
Incubation Time: 24 h
Result: Upregulated the expression of CPT1 and ACOX1; downregulated SREBP-1c, ACC, and FAS.

Cell Viability Assay

Cell Line: human renal proximal tubular (HK-2) cells
Concentration: 3, 6, 12, 24, 48, 96, 192, 384, 768 μM
Incubation Time: 24 h
Result: Reduced HK-2 cell viability in a concentration-dependent manner.
Yielded a cell viability of 96.20% at 6 μM for 24 h.

Apoptosis Analysis

Cell Line: human renal proximal tubular (HK-2) cells
Concentration: 6 μM
Incubation Time: 24 h
Result: Significantly increased HK-2 cell apoptosis
Significantly decreased protein expression of anti-apoptotic Bcl-2 and Bcl-xl.
Significantly reduced mRNA levels of Bcl-2 and Bcl-xl.

Cell Autophagy Assay

Cell Line: human renal proximal tubular (HK-2) cells
Concentration: 6 μM
Incubation Time: 24 h
Result: Induced formation of numerous double-membrane autophagosomes and autophagic vacuoles containing degraded organelles.
Significantly increased green fluorescence (LC3II accumulation).
Significantly increased LC3II/LC3I ratio and Beclin-1 protein expression.
Significantly elevated mRNA levels of LC3 and Beclin-1.

Cell Viability Assay

Cell Line: human renal proximal tubular (HK-2) cells
Concentration: 6 μM; 6 μM plus 3-MA
Incubation Time: 48 h
Result: Resulted in a cell viability of 50.71% when used alone for 48 h.
Increased cell viability to 89.06% when co-incubated with 3-MA.

Cell Viability Assay

Cell Line: fully differentiated 3T3-L1 adipocytes
Concentration: 10, 20, 30, 40, 50 μM
Incubation Time: 24 h; 48 h; 72 h
Result: Increased cell viability relative to untreated control cells by 10.3%, 12.0%, and 10.8% at 30, 40, and 50 μM for 24 h, respectively.

Real Time qPCR

Cell Line: fully differentiated 3T3-L1 adipocytes
Concentration: 50 μM
Incubation Time: 12 h
Result: Significantly decreased mRNA expression of HSL, PPARγ, and perilipin A.
Significantly increased ATGL mRNA expression.

Western Blot Analysis

Cell Line: fully differentiated 3T3-L1 adipocytes
Concentration: 30, 50 μM (ATGL and HSL phosphorylation analysis); 30, 50 μM (ERK phosphorylation, PPARγ, and perilipin A analysis)
Incubation Time: 36 h (ATGL and HSL phosphorylation analysis); 24 h (ERK phosphorylation, PPARγ, and perilipin A analysis)
Result: Elevated ATGL protein expression at 30 μM after 36 h treatment.
Raised HSL phosphorylation at Ser660 by 54.2% relative to controls at 50 μM after 36 h treatment, while exerting no influence on HSL phosphorylation at Ser563 and Ser565.
Increased ERK phosphorylation by 55.6% relative to controls at 50 μM after 24 h treatment.
Downregulated PPARγ and perilipin A protein levels relative to controls at 50 μM after 24 h treatment.

Cell Viability Assay

Cell Line: RAW 264.7 macrophages, HAEC primary aortic endothelial cells
Concentration: 20, 25, 30 μM (RAW 264.7); 30, 35, 40 μM (HAEC)
Incubation Time: 24 h
Result: Showed no cytotoxicity to HAEC cells at 30, 35, or 40 μM, with cell viability remaining above 70%.
Maintained RAW 264.7 cell viability near 100% at 20 and 25 μM, and above 75% at 30 μM.
Confirmed no significant cell death in RAW 264.7 cells via Live/Dead staining at 20, 25, or 30 μM.
...(内容过长已截断)
体内研究
(In Vivo)

Alisol A 24-acetate (compound 24A) (0.5 g/kg;口服;每日;持续 6 个月) 可诱导雌性 Sprague Dawley 大鼠产生肾毒性,肾脏的病理变化以及 Kim-1、Clusterin 和 TFF-3 的蛋白水平显著升高可证明这一点。
Alisol A 24-acetate (24A) (30 mg/kg;口服;每日 1 次;连续 7 天) 可通过激活 PI3K/AKT 通路,抑制神经炎症与细胞凋亡、改善神经及认知功能并恢复脑代谢,从而缓解雄性 C57BL/6J 小鼠的全脑缺血再灌注损伤。
Alisol A 24-acetate (AA) (20-30 μM;左侧后腹足注射;单次给药) 可提高 MRSA 感染的 Galleria mellonella 幼虫的存活率。
Alisol A 24-acetate (100 μM;涂抹给药;每日 1 次;连续 8 天) 可降低小鼠 MRSA 皮肤伤口感染模型中的 MRSA 载菌量、促进伤口愈合并下调 IL-1β 的表达。

Animal Model: C57BL/6J (male, 12 weeks old, 25-30 g, global cerebral ischaemia-reperfusion injury induced by two-vessel occlusion)
Dosage: 30 mg/kg
Administration: p.o.; once daily; 7 consecutive days (initiated 24 hours after reperfusion)
Result: Ameliorated neurological deficit scores at days 1, 3, 5 and 7.
Improved learning and memory abilities, with shorter escape latency and travel distance, and longer residence time in the target quadrant.
Enhanced novel object recognition by raising discrimination index and time ratio.
Regulated brain metabolite levels by lowering Glx/Cr, MI/Cr, CHO/Cr and Taurine/Cr, and elevating GABA/Cr and NAA/Cr.
Suppressed activation of microglia and astrocytes in hippocampus and cortex.
Alleviated neuroinflammation and apoptosis, and decreased levels of IL-1β, TNF-α, iNOS, Bax/Bcl-2 and cleaved Caspase-3.
Protected neuronal morphology, increased neuronal quantity and dendritic spine density.
Activated PI3K/AKT pathway and elevated p-PI3K/PI3K and p-AKT/AKT ratios.
Animal Model: ICR (female, 6 weeks old)
Dosage: 100 μM
Administration: smear route; once daily; 8 days
Result: Reduced bacterial load in infected skin tissue.
Promoted wound healing with significant reduction in wound size over 8 days.
Increased epidermal thickness and collagen deposition in infected skin.
Decreased relative expression of the inflammatory cytokine IL-1β in infected tissue compared to the infected control group.
性状 固体
颜色 White to off-white

化学信息

分子量 532.75
分子式 C32H52O6
CAS No. 18674-16-3
别名 Alisol A 24-monoacetate; Alisol A monoacetate

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 7.25 mg/mL (13.61 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 50 mg/mL (93.85 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8771 mL9.3853 mL18.7705 mL46.9263 mL
5 mM0.3754 mL1.8771 mL3.7541 mL9.3853 mL
10 mM0.1877 mL0.9385 mL1.8771 mL4.6926 mL
15 mM0.1251 mL0.6257 mL1.2514 mL3.1284 mL
20 mM0.0939 mL0.4693 mL0.9385 mL2.3463 mL
25 mM0.0751 mL0.3754 mL0.7508 mL1.8771 mL
30 mM0.0626 mL0.3128 mL0.6257 mL1.5642 mL
40 mM0.0469 mL0.2346 mL0.4693 mL1.1732 mL
50 mM0.0375 mL0.1877 mL0.3754 mL0.9385 mL
60 mM0.0313 mL0.1564 mL0.3128 mL0.7821 mL
80 mM0.0235 mL0.1173 mL0.2346 mL0.5866 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

24-乙酰泽泻醇 A 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础